Key Points Immuron submits Investigational new drug (IND) application to FDA for clinical development of IMM-529 as product ...

Lax hospital hygiene is dooming patients to sickness and death from infections — whether it’s a new, rare organism or a ...

Dirty hospitals are a major cause of drug-resistant superbug deaths. Learn more about the shocking statistics.

Health care staff skip cleaning their hands between patients, and hospitals fail to clean rooms and medical equipment — even ...

Some of the key facts of the Clostridium Difficile Infections Market Report: ...

Fecal microbiota transplant was noninferior to vancomycin as the initial treatment for C. diff in a randomized, open-label trial. Transplant showed slightly higher cure rates without recurrence and ...

As “nightmare bacteria” evolve and become more drug-resistant, going into a hospital will be an increasingly dangerous ...

Immuron (IMRN) announced that it has submitted an Investigational New Drug, or IND, application to the FDA for clinical development of IMM-529.

Hip-Hop has equally thrived on legendary quarrels and strong relationships. Latto recently revealed whether she would ever be ...

Confused about prebiotics vs. probiotics? Here, the key differences, health benefits, and how to choose the right one to ...

Lumen is led by CEO Brian Finrow, a former senior vice president at Adaptive Biotechnologies, and Chief Science Officer Jim Roberts, the former head of basic sciences at the Fred Hutchinson Cancer ...